Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Long-Term (1-Year) Seizure Freedom with Adjunctive Perampanel in Pediatric Patients (Aged 4–<12 Years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Post Hoc Analysis of Study 311
Epilepsy/Clinical Neurophysiology (EEG)
Epilepsy/Clinical Neurophysiology (EEG) Posters (7:00 AM-5:00 PM)
010

Assess if seizure-freedom rates with adjunctive perampanel during the 311 Core Study (NCT02849626) are maintained long-term in pediatric patients with POS (with/without secondarily generalized seizures [SGS]) or PGTCS.
In the US, perampanel is approved for POS (adjunctive/monotherapy) in patients aged ≥4 years and PGTCS (adjunctive) in patients aged ≥12 years. Seizure freedom is maintained long-term with perampanel in patients aged ≥12 years with SGS or PGTCS.
Seizure-freedom rates were assessed in patients who achieved seizure freedom during the Core Study Maintenance Period and then remained seizure free for 6 and/or 12 months (calculated from the start of their seizure-free period). Data were stratified by concomitant enzyme-inducing anti-seizure medications (EIASMs) (with/without) and age (4–<7/7–<12 years).
For POS, 13/17 (76.5%) seizure-free patients during the Core Study remained seizure free for 6 months (with EIASMs, n=3/5 [60.0%]; without EIASMs, n=10/12 [83.3%]; 4–<7 years, n=1/3 [33.3%]; 7–<12 years, n=12/14 [85.7%]), and 6/11 (54.5%) remained seizure free for 12 months (with EIASMs, n=2/5 [40.0%]; without EIASMs, n=4/6 [66.7%]; 4–<7 years, n=0/1; 7–<12 years, n=6/10 [60.0%]). For SGS, 3/8 (37.5%) seizure-free patients remained seizure free for 6 months (with EIASMs, n=0/1; without EIASMs, n=3/7 [42.9%]; 4–<7 years, n=0/3; 7–<12 years, n=3/5 [60.0%]), and 1/5 (20.0%) patients remained seizure free for 12 months (with EIASMs, n=0/1; without EIASMs, n=1/4 [25.0%]; 4–<7 years, n=0/2; 7–<12 years, n=1/3 [33.3%]). For PGTCS, 6/10 (60.0%) seizure-free patients remained seizure free for 6 months (no PGTCS seizure-free patients received EIASMs; 4–<7 years, n=1/2 [50.0%]; 7–<12 years, n=5/8 [62.5%]), and 3/7 (42.9%) patients remained seizure free for 12 months (4–<7 years, n=0/1; 7–<12 years, n=3/6 [50.0%]).

Despite small patient numbers, seizure-freedom rates are maintained during long-term perampanel treatment in pediatric patients, consistent with analyses in adolescents/adults.

Funding: Eisai Inc.
Authors/Disclosures
Robert Flamini, MD
PRESENTER 		Dr. Flamini has received personal compensation in the range of $0-$499 for serving as a Consultant for Biocodex. Dr. Flamini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Flamini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals.
No disclosure on file
Manoj Malhotra, MD Dr. Malhotra has received personal compensation for serving as an employee of Eisai.
Stella L. Ngo, PhD Dr. Ngo has received personal compensation for serving as an employee of Neurelis Inc.. Dr. Ngo has received personal compensation for serving as an employee of Neurelis Inc..